StockData
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. (WHWK) stock

WHWKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$3.13+0.05 (+1.62%)

Close on Nov 18, 2026Market cap $178.44MP/E –Yield –

Whitehawk Therapeutics cash

Cash and short-term investments held at the end of each period.

Whitehawk Therapeutics's cash was $190.00M at Jun 30, 2026. For fiscal 2025 it was $145.70M, up 208.7% from the year before. Over ten years it grew 39.7% a year on average. The highest annual figure on record is $172.60M in fiscal 2022.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$145.70M+208.7%
FY2024Dec 31, 2024$47.20M-56.6%
FY2023Dec 31, 2023$108.80M-37.0%
FY2022Dec 31, 2022$172.60M+15.8%
FY2021Dec 31, 2021$148.99M+3244.3%
FY2020Dec 31, 2020$4.46M-88.4%
FY2019Dec 31, 2019$38.52M-38.5%
FY2018Dec 31, 2018$62.61M+209.0%
FY2017Dec 31, 2017$20.26M+1121.0%
FY2016Dec 31, 2016$1.66M-67.7%
FY2015Dec 31, 2015$5.14M+97642.9%
FY2014Dec 31, 2014$5.26K-16.2%
FY2013Dec 31, 2013$6.28K+36.4%
FY2012Dec 31, 2012$4.61K+11.7%
FY2011Dec 31, 2011$4.13K-84.7%
FY2010Dec 31, 2010$26.90K+141.4%
FY2009Dec 31, 2009$11.14K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$190.00M+7.2%
Q1 FY2026Mar 31, 2026$123.00M-46.8%
Q4 FY2025Dec 31, 2025$145.70M+208.7%
Q3 FY2025Sep 30, 2025$162.60M+159.7%
Q2 FY2025Jun 30, 2025$177.20M+125.4%
Q1 FY2025Mar 31, 2025$231.10M+161.7%
Q4 FY2024Dec 31, 2024$47.20M-56.6%
Q3 FY2024Sep 30, 2024$62.60M-47.5%
Q2 FY2024Jun 30, 2024$78.60M-41.7%
Q1 FY2024Mar 31, 2024$88.30M-41.6%
Q4 FY2023Dec 31, 2023$108.80M-37.0%
Q3 FY2023Sep 30, 2023$119.30M-34.8%
Q2 FY2023Jun 30, 2023$134.90M+13.6%
Q1 FY2023Mar 31, 2023$151.20M+16.4%
Q4 FY2022Dec 31, 2022$172.60M+15.8%
Q3 FY2022Sep 30, 2022$183.00M+13.4%
Q2 FY2022Jun 30, 2022$118.74M+222.5%
Q1 FY2022Mar 31, 2022$129.85M+232.9%
Q4 FY2021Dec 31, 2021$148.99M+3244.3%
Q3 FY2021Sep 30, 2021$161.38M+241.3%
Q2 FY2021Jun 30, 2021$36.82M-17.9%
Q1 FY2021Mar 31, 2021$39.01M+12.8%
Q4 FY2020Dec 31, 2020$4.46M-88.4%
Q3 FY2020Sep 30, 2020$47.28M+9.0%
Q2 FY2020Jun 30, 2020$44.86M-6.8%
Q1 FY2020Mar 31, 2020$34.58M-35.3%
Q4 FY2019Dec 31, 2019$38.52M-38.5%
Q3 FY2019Sep 30, 2019$43.39M-36.9%
Q2 FY2019Jun 30, 2019$48.16M-30.0%
Q1 FY2019Mar 31, 2019$53.42M+288.1%
Q4 FY2018Dec 31, 2018$62.61M+209.0%
Q3 FY2018Sep 30, 2018$68.81M+176.6%
Q2 FY2018Jun 30, 2018$68.78M+138.0%
Q1 FY2018Mar 31, 2018$13.76M-60.9%
Q4 FY2017Dec 31, 2017$20.26M+1121.0%
Q3 FY2017Sep 30, 2017$24.88M+1801.5%
Q2 FY2017Jun 30, 2017$28.90M–
Q1 FY2017Mar 31, 2017$35.19M–
Q4 FY2016Dec 31, 2016$1.66M–
Q3 FY2016Sep 30, 2016$1.31M–

More Whitehawk Therapeutics figures

See a number that looks wrong?